McAlindon TE, et al. - Researchers assessed the intraarticular onabotulinumtoxinA 400 U and 200 U in reducing symptoms of knee osteoarthritis (OA) in patients with nociceptive pain. Findings demonstrated that the daily average pain score was reduced by approximately 2 points for all treatments (week 8). The enrollment consisted of adults with knee OA and a painDETECT questionnaire score of ≥12 (indicating nociceptive pain). In patients with knee OA, onabotulinumtoxinA was not significantly different from placebo in reducing average pain score at week 8 compared with baseline. No safety concerns were brought to light.